Novo Nordisk Reports Headline Results from P-IIIb (STEP UP) Study of Semaglutide 7.2mg in Obese Adults without Diabetes
Shots:
- The P-IIIb (STEP UP) study assessed semaglutide (7.2mg) vs semaglutide (2.4mg) & PBO as an adjunct to lifestyle intervention in obese adults (n=1,407; BMI ≥30kg/m^2) without diabetes for 72wks. STEP program also includes STEP UP T2D study of semaglutide (7.2mg) in obese adults (n=512) with T2D for 72wks.
- Study met its 1EP, depicting superior weight loss of 20.7% (7.2mg) vs 17.5% (2.4mg) & 2.4% (PBO) as well as 33.2% vs 16.7% & 0% had a weight loss of 25% or more after 72wks. With the treatment policy estimand, weight losses were 18.7% vs 15.6% & 3.9%
- Full findings from the STEP UP study will be featured at future conferences while the results from STEP UP T2D trial are anticipated within the next few months
Ref: Novo Nordisk | Image: Novo Nordisk
Related News:- Novo Nordisk Expands its Partnership with Valo Health to Discover and Develop Novel Therapies for Cardiometabolic Diseases
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
